Wolverine stack (BPC-157 + TB-500): research

Wolverine stack (BPC-157 + TB-500) dosage

Typical reported dose: 0.5 mg each of BPC-157 and TB-500 once a day

• Equal parts, daily reports: 1 mg total: BPC-157 0.5 mg + TB-500 0.5 mg daily. once daily, under the skin. Reported by users, occasional report. Studied in: Adults discussing self-use; products and outcomes unverified. (source)
• Five dosing days, two off-days: 1 mg total on dosing days: BPC-157 0.5 mg + TB-500 0.5 mg. once daily on five days each week, under the skin. Reported by users, occasional report. Studied in: Adults discussing self-use; products and outcomes unverified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Wolverine stack (BPC-157 + TB-500) side effects and risks

Reported side effects

• Injection-site pain, redness or swelling: No reliable blend event rate; reports lack a denominator., moderate. Pause for persistent reactions; spreading heat or redness needs prompt assessment. (source)
• Serious allergic or immune reaction: FDA flags immune reaction risk; blend incidence is unknown., serious. Breathing trouble, throat swelling or collapse needs emergency care. (source)
• Infection from a contaminated injection: Product related risk; no measured blend rate., serious. Seek urgent care for fever with spreading redness or severe injection-site pain. (source)
• Darkening of skin and gums: FDA described one BPC/TB500 user with recurrence on re exposure; dose and causality uncertain., moderate. Stop further exposure and seek assessment for new widespread pigment changes. (source)

Stop and get help if

• Trouble breathing, throat swelling, collapse or fainting after an injection: Stop and call emergency services now.
• Hot, painful, spreading redness or swelling at an injection site: Stop injections and seek urgent same-day care; fever, confusion or fast breathing needs emergency care.

Who should avoid it

• pregnant: Precaution: no blend pregnancy safety data; pregnancy was excluded from the knee report.
• breastfeeding: Precaution: milk transfer and infant effects have not been studied for the blend.
• tryingToConceive: Precaution: reproductive safety and a safe washout period are unknown.
• under18: Precaution: no pediatric blend safety or dosing studies found.
• activeCancer: Precaution: ingredients promote blood-vessel growth in lab studies; effects on human tumors are unknown.
• cancerHistory: Review prior cancer with the treating clinician; long-term tumor effects have not been measured.
• kidneyDisease: Blend clearance and dose changes in kidney disease are unknown.
• liverDisease: Blend clearance and dose changes in liver disease are unknown.
• bleedingDisorder: Precaution for needle-related bruising and bleeding, especially with muscle injection.
• surgeryPlanned: Tell the surgical team about all ingredients; no safe perioperative stopping interval is established.
• testedAthlete: BPC-157 and TB-500 are prohibited at all times under the 2026 WADA list.
• other: Avoid re-exposure after a serious reaction; peptide impurities can trigger immune reactions.

Interactions

• Duplicate peptide products: Amounts add across vials and blends. No combination study establishes a safe total exposure.
• Oral anticoagulants: Muscle injections can increase bleeding or bruising. This is a needle-related risk; a chemical interaction with the blend is untested.

Product quality risks

• Label names may hide different TB4 molecules; fragment and full-length products are not interchangeable.
• FDA-reviewed ingredient COAs lacked some content, aggregate or endotoxin controls. HPLC purity alone cannot establish injection safety.
• Unauthorized injections may have wrong amounts, undeclared ingredients, microbes or endotoxins; blend defect rates are unknown.

How Wolverine stack (BPC-157 + TB-500) works

Ingredient experiments suggest effects on blood-vessel growth, cell movement and repair signals. Most findings come from animals and cells. They do not establish that a mixed vial works better. Full-length thymosin beta4 and the shorter TB-500 fragment are different molecules.

• BPC-157: VEGFR2–Akt–eNOS: More vessel-growth signaling in animal and cell experiments.
• Full-length TB4: actin and cell movement: Wound-repair activity cannot simply be assigned to every TB-500 product.

Half-life: No human half-life established for the premixed blend.